Prescribing information

 

   

Kymriah® is indicated for the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse, and adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1

Global manufacturing network to meet the needs of patients worldwide

Map of the world with marked areas representing global manufacturing network.

DESIGNED TO MEET THE GROWING DEMANDS OF A TRANSFORMATIVE & CURATIVE TREATMENT

circular icon with the following text inside: 3,700 batched to date,
circular icon with the following text inside: 7 sites worldwide
circular icon with the following text inside: Commitmentto no queue*
 

*Novartis is committed to ensuring slot availability and minimised treatment delay for as many patients as possible.

References

  1. Kymriah Summary of Product Characteristics; April 2020.
  2. Data on file. Kymriah. Novartis Pharmaceuticals Corp; October 2020.
  3. Pharmatech. Novartis Gets EMA Approval for Two European Commercial CAR-T Manufacturing Sites. Available at: https://www.pharmtech.com/view/novartis-gets-ema-approval-for-two-europe... [Accessed December 2021].
Rate this content: 
Average: 5 (1 vote)
UK | September 2021 | 144106
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]